Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIS-GHR-LRx Monotherapy in Acromegaly
NCT04522180Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Jul 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 10
01
Overview
A Phase 2 trial of cimdelirsen in acromegaly, sponsored by Ionis Pharmaceuticals. Started Jan 2021; status: completed.
02
Drugs
cimdelirsen
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT04522180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522180.